LRRK2 rare-variant per-domain genetic burden in Parkinson’s Disease.

Senkevich K, Parlar SC, Chantereault C, Yu E, Ahmad J, Ruskey JA, Asayesh F, Spiegelman D, Waters C, Monchi O, Dauvilliers Y, Dupré N, Miliukhina I, Timofeeva A, Emelyanov A, Pchelina S, Greenbaum L, Hassin-Baer S, Alcalay RN, Gan-Or ZAre rare heterozygous SYNJ1 variants associated with Parkinson’s disease?  NPJ Parkinsons Dis. 2024. Preprint, PubMed

Plasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson’s disease pathogenesis.

Somerville EN, James A, Beetz C, Schwieger R, Barrel G, Kandaswamy KK, Iurascu MI, Bauer P, Ta M, Iwaki H, Senkevich KYu E, Alcalay RN and Gan-Or ZPlasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson’s disease pathogenesis. Under review. Preprint, Pubmed

Heterozygous RAB3A variants cause cerebellar ataxia by a partial loss-of-function mechanism.

Hengel H, Hannan SB, Reich S, Beijer D, Roller J, Gilsbach BK, Gloeckner CJ, Greene D, Timmann D, Depienne C, Mumford A, O’Driscoll M, Nemeth AH, Lundberg J, Rodan LH, Bruel AL, Delanne J, Baets J, Gan-Or Z, Rouleau G, Suchowersky O, Estiar MA, Reich S, Toro C, Züchner S, Hazan J, Pétursson H, Harmuth F, Bauer C, Bauer P, Turro E, Lambright D, Schöls L and Synofzik M. Heterozygous RAB3A variants cause cerebellar ataxia by a partial loss-of-function mechanism. Under review. Preprint, PubMed

Digenic inheritance of mutations in SPG7 and AFG3L2 causes motor neuron and cerebellar disorders.

Estiar MAYu E, Varghaei P, Ross JP, Ashtiani S, Bayne AN, Coarelli G, Timmann D, lockgether T, Beijer D, Mengel D, Coutelier M, Project MinE ALS Sequencing Consortium, Dion PA, Suchowersky O, Ewenczyk C, Goizet C, Van Damme P, Al-Chalabi A, Zuchner S, Synofzik M, Veldink JH, Trempe JF, Durr A, Rouleau GA and Gan-Or ZDigenic inheritance of mutations in SPG7 and AFG3L2 causes motor neuron and cerebellar disorders. Under review. Preprint, PubMed

Lack of Epistatic Interaction of SNCA with APOE in Synucleinopathies.

Saini P, Yu EEstiar MAKrohn L, Mufti K, Rudakou URuskey JAAsayesh F, Laurent SB, Spiegelman D, Trempe JF, Quinnell TG, Oscroft N, Arnulf I, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Sonka K, Kemlink D, Oertel W, Kaivola K, International LBD Genomics Consortium, Janzen A, Plazzi G, Antelmi E, Biscarini F, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Cochen De Cock V, Monaca CC, Grosset D, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Anselmi V, Ibrahim A, Stefani A, Hogl B, Hu MTM, Scholz SW and Gan-Or ZLack of Epistatic Interaction of SNCA with APOE in Synucleinopathies. Under review. Preprint, PubMed

 Advancing Parkinson’s Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN).

Cressatti M, Pinilla-Monsalve GD, Blais M, Normandeau CP, Degroot C, Kathol I, Borard S, Bendas A, Camicioli R, Dupré N, Gan-Or Z, Grimes DA, Kalia LV, MacDonald PA, McKeown MJ, Martino D, Miyasaki JM, Schlossmacher MG, Stoessl AJ, Strafella AP, Fon EA and Monchi O. Advancing Parkinson’s Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN). Under review. Preprint, PubMed

GLON5 Frequency in idiopathic REM sleep behavior disorder: a multicenter study. 

Postuma RB, Vorasoot N, St. Louis EK, Pelletier A, Lim MM, Elliott JE, Gagnon JF, Gan-Or Z, Forsberg LK, Fields JA, Ross OA, Singer W, Huddleston DE, Bliwise DL, Avidan AY, Howell MJ, Schenck CH, McLeland J, Davis AA, Criswell SR, Videnovic A, During EH, Miglis MG, Boeve BF, Ju YES, McKeon A and the North American Prodromal Synucleinopathy (NAPS) Consortium. IGLON5 Frequency in idiopathic REM sleep behavior disorder: a multicenter studyNeurol Neuroimmunol Neuroinflamm. 2024. PubMed

Genome-wide association study of glucocerebrosidase activity modifiers.

Somerville EMKrohn LSenkevich KYu E, Ahmad JAsayesh FRuskey JA, Spiegelman D, Fahn S, Waters C, Sardi P, Alcalay RN and Gan-Or ZGenome-wide association study of glucocerebrosidase activity modifiers. Under review. Preprint, PubMed

RAB32 Ser71Arg in autosomal dominant Parkinson’s disease: linkage, association, and functional analyses.

Gustavsson EK, Follett J, Trinh J, Barodia SK, Real R, Liu Z, Grant-Peters M, Fox JD, Cresswell S, Stoessl AJ, Rajput A, Rajput AH, Auer R, Tilney R, Sturm M, Haack TB, Lesage S, Tesson C, Brice A, Vilarino-Guell C, Ryten M, Goldberg MS, West AB, Hu MT, Morris HR, Sharma M, Gan-Or Z, Samanci B, Lis P, Tocino TP, Amouri R, Ben Sassi S, Hentati F, Tonelli F, Alessi DB and Farrer MJ. RAB32 Ser71Arg in autosomal dominant Parkinson’s disease: linkage, association, and functional analyses. Lancet Neurology. 2024. PreprintPubMed

Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)

Chertkow H, Phillips N, Rockwood K, Anderson N, Andrew MK, Bartha R, Beaudoin C, Bélanger N, Bellec P, Belleville S, Bergman H, Best S, Bethell J, Bherer L, Black S, Borrie M, Camicioli R, Carrier J, Cashman N, Chan S, Crowshoe L, Cuello C, Dang-Vu T, Das S, Dixon RA, Ducharme S, Einstein G,Evans AC, Fahnestock M, Feldman H, Ferland G, Finger E, Fisk J, Fogarty J, Fon E, Gan-Or Z, Gauthier S, Greenwood C, Henri-Bellemare C, Herrmann N, Hogan DB, Hsiung R, Itzhak I, Jacklin K, Lanctôt K, Lim A, MacKenzie I, Masellis M, Maxwell C, McAiney C, McGilton K, McLaurin J, Mihailidis A, Mohades Z, Montero-Odasso M, Morgan D, Naglie G, Nygaard H, O’Connell M, Pilon R, Rajah MN, Rapoport M, Roach P, Robillard JM, Rogaeva E, Rosa-Neto P, Rylett J, Sadavoy J, St. George-Hyslop P, Seitz D, Smith E, Stefanovic J, Tierney M, Vedel I, Walker JD, Wellington C, Whitehead V and Wittich W. Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)J Alzheimers Dis. 2024. PubMed